Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors? - Wikidata - awgldk - TriplyDB

Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors?

Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors?

http://www.wikidata.org/entity/Q37600856

about

Impact of genetic and renovascular chronic arterial hypertension on the acute spatiotemporal evolution of the ischemic penumbra: a sequential study with MRI in the rat.Candesartan restores pressure-induced vasodilation and prevents skin pressure ulcer formation in diabetic mice.Treatment options and considerations for hypertensive patients to prevent dementia.AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.Current therapeutic strategies to mitigate the eNOS dysfunction in ischaemic stroke.

P2860

Q34627587-C29EDC12-DC25-49E9-8CD3-82E41F016EA8 Q35382532-F7D51362-D059-4706-8A46-2FEB6ECF57C2 Q36377901-9FB496AA-0801-408C-8849-ADF0711D3EC8 Q36573232-FF61E74C-3816-4C10-9033-8EF6E43CC57B Q37600876-73F14685-BCE9-41FF-99EA-CC45A0F15F5F Q37971308-F8047BFF-71EC-44E2-9AF3-3ABF2107E9C4

P2860

Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors?

http://www.wikidata.org/entity/Q37600856

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Angiotensin AT1-receptor block ...... -converting enzyme inhibitors?

@en

Angiotensin AT1-receptor block ...... -converting enzyme inhibitors?

@nl

type

label

Angiotensin AT1-receptor block ...... -converting enzyme inhibitors?

@en

Angiotensin AT1-receptor block ...... -converting enzyme inhibitors?

@nl

prefLabel

Angiotensin AT1-receptor block ...... -converting enzyme inhibitors?

@en

Angiotensin AT1-receptor block ...... -converting enzyme inhibitors?

@nl

P1433

Q37600856-6221EB6F-EA0B-4320-BF56-9B8EF8BAE620

P1476

Q37600856-7649FA03-E252-4929-A00F-2FE7D95CCA38

P2093

Q37600856-1115AEB5-D47D-4A09-A241-6274FB9608D2

Q37600856-26F6A198-3B2D-4530-8E5C-81A6925AD7F1

Q37600856-30562E79-CDD8-47C1-80C3-AE763BAB9198

Q37600856-3C6F0EF6-9648-47E0-8686-30FDAD6B9D16

Q37600856-44397D7B-B055-41F5-8621-9FF841033CEC

Q37600856-6058A994-192F-47F5-8F56-9824C7297C4A

Q37600856-7A750A39-E638-4FC3-9359-60318907D406

Q37600856-9DCE9B5A-3C9E-47F1-B315-CA66F1DB118A

Q37600856-BA3C7283-F0DD-4903-8F54-ACC9D10027F5

Q37600856-CD360A9C-F553-465A-8AAA-C010C0A80A29

P2860

Q37600856-00B15EED-71FB-4618-87CC-9AD2077C0D0D

Q37600856-04A10491-0F6E-4D6C-A484-B5542D60E6F8

Q37600856-06227D4B-BA47-4F18-BAE4-C48E087735BA

Q37600856-09973258-39F7-4292-B4F7-F4AB843EB2C6

Q37600856-0CB146B8-1D88-4800-9C3C-B099142A3119

Q37600856-1FA88EE3-1ECA-4B50-8994-3FBFCCEA35D7

Q37600856-1FB152D1-AF3B-4BA5-A135-01768496782B

Q37600856-267923C6-759A-4E07-8621-96F67CB493DB

Q37600856-2C69DF3A-7D4C-4DD3-820F-6809233ED89A

Q37600856-3073F2BD-05EC-4B9A-AA7D-B542B9F4D03E

P304

Q37600856-86A38591-2BC1-4476-B7BA-A65840A89408

P31

Q37600856-B098DFAB-59EF-4182-B8A5-A67F190B2CDA

P356

Q37600856-FB1257C9-80AA-4367-9CE7-243394086CE7

P433

Q37600856-E3C20BEB-415C-4B70-A95A-015E6F882AC1

P478

Q37600856-427E7BEE-0962-47E3-88F2-027ACD8FD8E2

P50

Q37600856-B0925FC1-FCFF-48E7-9992-0D2A01C02A41

P577

Q37600856-E9CB1491-07CC-4173-9993-56C9B518A381

P698

Q37600856-92A8CC73-4143-4F95-B417-BC04D7F1CEA0

P356

P1433

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

P1476

Angiotensin AT1-receptor block ...... -converting enzyme inhibitors?

@en

P2093

Adriana Albu

http://www.w3.org/2001/XMLSchema#string

Albert Fournier

http://www.w3.org/2001/XMLSchema#string

Florent Boutitie

http://www.w3.org/2001/XMLSchema#string

Hakim Mazouz

http://www.w3.org/2001/XMLSchema#string

Jean-Marie Serot

http://www.w3.org/2001/XMLSchema#string

Jean-Michel Achard

http://www.w3.org/2001/XMLSchema#string

Jiguang Wang

http://www.w3.org/2001/XMLSchema#string

Mohammed Temmar

http://www.w3.org/2001/XMLSchema#string

Olivier Godefroy

http://www.w3.org/2001/XMLSchema#string

Olivier Hanon

http://www.w3.org/2001/XMLSchema#string

P2860

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

Blood pressure and clinical outcomes in the International Stroke Trial

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Telmisartan, ramipril, or both in patients at high risk for vascular events.

The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats.

Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation.

P304

1289-1305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERN.09.88

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19769445

http://www.w3.org/2001/XMLSchema#string